Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Net Income towards Common Stockholders: 2022-2024

Historic Net Income towards Common Stockholders for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to -$88.7 million.

  • Stoke Therapeutics' Net Income towards Common Stockholders fell 45.09% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
  • As of FY2024, Stoke Therapeutics' Net Income towards Common Stockholders stood at -$88.7 million, which was up 15.38% from -$104.9 million recorded in FY2023.
  • Stoke Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$88.7 million during FY2024, with a 5-year trough of -$104.9 million in FY2023.
  • For the 3-year period, Stoke Therapeutics' Net Income towards Common Stockholders averaged around -$98.3 million, with its median value being -$101.2 million (2022).
  • In the last 5 years, Stoke Therapeutics' Net Income towards Common Stockholders declined by 3.59% in 2023 and then rose by 15.38% in 2024.
  • Stoke Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$101.2 million in 2022, then declined by 3.59% to -$104.9 million in 2023, then increased by 15.38% to -$88.7 million in 2024.